CBX3-targeted dual BET/PLK1 inhibition amplifies the effects of CDK4/6 inhibitors by disrupting BRD4/PLK1-mediated transcription and inducing cell-cycle arrest in prostate cancer (178). Here, DNER is linked to prostate cancer.